Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

China’s Simcere Jumps After 2011 Profit Beats Estimates

Don't Miss Out —
Follow us on:

March 7 (Bloomberg) -- Simcere Pharmaceutical Group, a Chinese drugmaker, jumped the most since 2008 after reporting that 2011 profit rose, beating analysts’ forecasts.

Simcere’s American depositary receipts jumped 7.5 percent, the biggest intraday gain since Dec. 30, to $8.90 by 10:23 a.m. in New York. The stock earlier rose as much as 19 percent, the largest advance since November 2008. Each ADR represents two common shares.

Net income of Simcere, based in Nanjing in China’s eastern Jiangsu province, rose 3.5 percent last year to 178.4 million yuan ($28.3 million), the company said in a statement today before U.S. markets opened. That exceeded the 142.4 million yuan average forecast of six analysts, according to data compiled by Bloomberg.

The company said fourth-quarter profit declined 27 percent from a year earlier to 42.8 million yuan, compared with a 39.4 million yuan average estimate of two analysts. Simcere was the biggest gainer on the Bloomberg China-US 55 Index of the most-traded Chinese stocks in the U.S. today.

To contact the reporter on this story: Belinda Cao in New York at lcao4@bloomberg.net

To contact the editor responsible for this story: Emma O’Brien at eobrien6@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.